Prevalence of risk factors for venous thromboembolism and aspirin resistance in Australian patients undergoing total hip and knee arthroplasty

被引:0
|
作者
van Oosterom, Nameer [1 ,2 ]
Barras, Michael [1 ,2 ]
Cottrell, Neil [1 ]
机构
[1] Univ Queensland, Sch Pharm, Brisbane, Qld, Australia
[2] Princess Alexandra Hosp, Pharm Dept, Brisbane, Qld, Australia
关键词
venous thromboembolism; aspirin resistance; risk factors; hip arthroplasty; knee arthroplasty; VTE prophylaxis; RECURRENT CARDIOVASCULAR EVENTS; PLATELET REACTIVITY; NATURAL-HISTORY; PROPHYLAXIS; THERAPY; DISEASE;
D O I
10.1111/imj.16407
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Aspirin is used for venous thromboembolism (VTE) prophylaxis after total hip and knee arthroplasty (THA/TKA). However, its efficacy is unclear in patients with multiple VTE risk factors and at risk of aspirin resistance (AR). Background and Aims: To determine the prevalence of risk factors for VTE and AR in patients after THA/TKA and to determine the relationship between risk factors and drugs prescribed for thromboprophylaxis. Methods: A retrospective cohort study of elective-THA/TKA in six Australian hospitals over a 1-year period. Medical records were manually reviewed to determine demographics, thromboprophylaxis regimen and presence of risk factors. The relationship between individual and cumulative risk factors with the thromboprophylaxis regimen was determined. Results: In total, 1011 patients were included with a mean (SD) age of 65.9 (+/- 11.0) years, and 56.4% were female. The five most prevalent risk factors were obesity (59.1%), age >= 65 years (58.2%), hypertension (45.3%), dyslipidaemia (35.9%) and diabetes (19.7%). Most patients had >= 1 risk factor for VTE (93.6%) and AR (93.6%), with 49.0% and 35.0% having >= 3 concurrent VTE and AR risk factors, respectively. The only significant relationship between risk factors and drugs was diabetes (P < 0.01). Rivaroxaban was more commonly used as the number of concurrent VTE risk factors increased (P < 0.05). Conclusion: Patients had a high prevalence of VTE and AR risk factors, suggesting aspirin may not be beneficial in many patients. Only diabetes was linked to the selection of thromboprophylaxis. Patients who received rivaroxaban had a greater average number of VTE risk factors. Guidelines should promote individualised prescribing in higher-risk patients.
引用
收藏
页码:1275 / 1282
页数:8
相关论文
共 50 条
  • [21] Aspirin vs Enoxaparin and Symptomatic Venous Thromboembolism in Hip or Knee Arthroplasty
    DeMik, David E.
    Mont, Michael A.
    Dunbar, Michael
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 329 (02): : 177 - 177
  • [22] Aspirin is Effective in Preventing Venous Thromboembolism After Knee or Hip Arthroplasty
    Baumgartner, Christine
    Maselli, Judith
    Auerbach, Andrew D.
    Fang, Margaret C.
    CIRCULATION, 2018, 137
  • [23] Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty The CRISTAL Randomized Trial
    Sidhu, Verinder S.
    Kelly, Thu-Lan
    Pratt, Nicole
    Graves, Stephen E.
    Buchbinder, Rachelle
    Adie, Sam
    Cashman, Kara
    Ackerman, Ilana
    Bastiras, Durga
    Brighton, Roger
    Burns, Alexander W. R.
    Chong, Beng Hock
    Clavisi, Ornella
    Cripps, Maggie
    Dekkers, Mark
    de Steiger, Richard
    Dixon, Michael
    Ellis, Andrew
    Griffith, Elizabeth C.
    Hale, David
    Hansen, Amber
    Harris, Anthony
    Hau, Raphael
    Horsley, Mark
    James, Dugal
    Khorshid, Omar
    Kuo, Leonard
    Lewis, Peter
    Lieu, David
    Lorimer, Michelle
    MacDessi, Samuel
    McCombe, Peter
    McDougall, Catherine
    Mulford, Jonathan
    Naylor, Justine Maree
    Page, Richard S.
    Radovanovic, John
    Solomon, Michael
    Sorial, Rami
    Summersell, Peter
    Tran, Phong
    Walter, William L.
    Webb, Steve
    Wilson, Chris
    Wysocki, David
    Harris, Ian A.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 328 (08): : 719 - 727
  • [24] Prevalence of Osteoporosis in Osteoarthritic Patients Undergoing Total Hip or Total Knee Arthroplasty
    Labuda, Anna
    Papaioannou, Alexandra
    Pritchard, Janet
    Kennedy, Courtney
    DeBeer, Justin
    Adachi, Jonathan D.
    ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION, 2008, 89 (12): : 2373 - 2374
  • [25] PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP AND KNEE ARTHROPLASTY
    LIEBERMAN, JR
    GEERTS, WH
    JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1994, 76A (08): : 1239 - 1250
  • [26] Does Aspirin Have a Role in Venous Thromboembolism Prophylaxis in Total Knee Arthroplasty Patients?
    Bozic, Kevin J.
    Vail, Thomas P.
    Pekow, Penelope S.
    Maselli, Judith H.
    Lindenauer, Peter K.
    Auerbach, Andrew D.
    JOURNAL OF ARTHROPLASTY, 2010, 25 (07): : 1053 - 1060
  • [27] Compliance with Australian Orthopaedic Association guidelines does not reduce the risk of venous thromboembolism after total hip and knee arthroplasty
    Badge, Helen
    Churches, Tim
    Naylor, Justine M.
    Xuan, Wei
    Armstrong, Elizabeth
    Gray, Leeanne
    Fletcher, John
    Gosbell, Iain
    Lin, Chung-Wei Christine
    Harris, Ian A.
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [28] Compliance with Australian Orthopaedic Association guidelines does not reduce the risk of venous thromboembolism after total hip and knee arthroplasty
    Helen Badge
    Tim Churches
    Justine M. Naylor
    Wei Xuan
    Elizabeth Armstrong
    Leeanne Gray
    John Fletcher
    Iain Gosbell
    Chung-Wei Christine Lin
    Ian A. Harris
    Scientific Reports, 14
  • [29] Direct Costs of Aspirin versus Warfarin for Venous Thromboembolism Prophylaxis after Total Knee or Hip Arthroplasty
    Gutowski, Christina J.
    Zmistowski, Benjamin M.
    Lonner, Jess H.
    Purtill, James J.
    Parvizi, Javad
    JOURNAL OF ARTHROPLASTY, 2015, 30 (09): : 36 - 38
  • [30] Risks of major bleeding and venous thromboembolism in patients undergoing total hip or total knee arthroplasty using therapeutic dosages of DOACs
    Smeets, Mark J. R.
    Kristiansen, Eskild Bendix
    Nemeth, Banne
    Huisman, Menno V.
    Cannegieter, Suzanne C.
    Pedersen, Alma Becic
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2024, 57 (07) : 1249 - 1255